Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer

Clin Cancer Res. 2024 May 15;30(10):2005-2007. doi: 10.1158/1078-0432.CCR-24-0251.

Abstract

Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cell Cycle Proteins* / antagonists & inhibitors
  • Cell Cycle Proteins* / genetics
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Humans
  • Mutation*
  • Neoplasm Metastasis
  • Polo-Like Kinase 1*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Serine-Threonine Kinases* / antagonists & inhibitors
  • Protein Serine-Threonine Kinases* / genetics
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Proto-Oncogene Proteins* / antagonists & inhibitors
  • Proto-Oncogene Proteins* / genetics